<html lang="en" class="pb-page js" data-request-id="94d61dfeb446f1b7-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d61dfeb446f1b7-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/HCvEcfIR8jlt3xn-_fwOTzR4TAFF2oAi4t0CJZquAHYV4L95aPEPapIHRgsubZoOw6GJ_txjsE8K9gSXvAFWZg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d61dfeb446f1b7-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.4426933018868322"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease">
<meta name="topics" content="Infectious Disease General|Global Health|HIV/AIDS">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1909512","title":"Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection","category":"Research","type":"Original Article","topics":"Infectious Disease General|Global Health|HIV/AIDS","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-03-19T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Infectious Disease General|Global Health|HIV/AIDS\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1909512","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d61dfeb446f1b7-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection"><meta name="dc.Creator" content="Chloe Orkin"><meta name="dc.Creator" content="Keikawus Arasteh"><meta name="dc.Creator" content="Miguel Górgolas Hernández-Mora"><meta name="dc.Creator" content="Vadim Pokrovsky"><meta name="dc.Creator" content="Edgar T. Overton"><meta name="dc.Creator" content="Pierre-Marie Girard"><meta name="dc.Creator" content="Shinichi Oka"><meta name="dc.Creator" content="Sharon Walmsley"><meta name="dc.Creator" content="Chris Bettacchi"><meta name="dc.Creator" content="Cynthia Brinson"><meta name="dc.Creator" content="Patrick Philibert"><meta name="dc.Creator" content="Johan Lombaard"><meta name="dc.Creator" content="Marty St. Clair"><meta name="dc.Creator" content="Herta Crauwels"><meta name="dc.Creator" content="Susan L. Ford"><meta name="dc.Creator" content="Parul Patel"><meta name="dc.Creator" content="Vasiliki Chounta"><meta name="dc.Creator" content="Ronald D’Amico"><meta name="dc.Creator" content="Simon Vanveggel"><meta name="dc.Creator" content="David Dorey"><meta name="dc.Creator" content="Amy Cutrell"><meta name="dc.Creator" content="Sandy Griffith"><meta name="dc.Creator" content="David A. Margolis"><meta name="dc.Creator" content="Peter E. Williams"><meta name="dc.Creator" content="Wim Parys"><meta name="dc.Creator" content="Kimberly Y. Smith"><meta name="dc.Creator" content="William R. Spreen"><meta name="dc.Description" content="Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.We conducted a phase 3, randomized, open-label trial in which adults wit..."><meta name="Description" content="Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.We conducted a phase 3, randomized, open-label trial in which adults wit..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-03-19"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1909512"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202003193821209"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa1904398"><meta name="dc.Relation" content="10.1056/NEJMe2002199"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1909512">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1909512">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1909512">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection | NEJM">
        <meta property="og:title" content="Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1909512">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/ced5a908-c07e-46b8-bcef-ba4bab38c549/nejmoa1909512_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/ced5a908-c07e-46b8-bcef-ba4bab38c549/nejmoa1909512_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency
virus type 1 (HIV-1) infection. We conducted a phase 3, randomized, open-label trial
in which adults wi...">
        <meta name="twitter:description" content="Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency
virus type 1 (HIV-1) infection. We conducted a phase 3, randomized, open-label trial
in which adults wi...">
    


    
    
        <meta property="og:image:width" content="2217">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1909512">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1909512">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1909512;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2020.382.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1909512" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1909512" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1909512" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1909512" class="inputDoi"><input type="hidden" value="C. Orkin and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:1124-1135" class="inputCitation"><input type="hidden" value="03-04-2020" class="inputEPubDate"><input type="hidden" value="March 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d61dfeb446f1b7-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Chloe</span> <span property="familyName">Orkin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Keikawus</span> <span property="familyName">Arasteh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Miguel</span> <span property="familyName">Górgolas Hernández-Mora</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vadim</span> <span property="familyName">Pokrovsky</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Edgar T.</span> <span property="familyName">Overton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pierre-Marie</span> <span property="familyName">Girard</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shinichi</span> <span property="familyName">Oka</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+19</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sharon</span> <span property="familyName">Walmsley</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chris</span> <span property="familyName">Bettacchi</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1148-6985" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1148-6985</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cynthia</span> <span property="familyName">Brinson</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Patrick</span> <span property="familyName">Philibert</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Johan</span> <span property="familyName">Lombaard</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marty</span> <span property="familyName">St. Clair</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Herta</span> <span property="familyName">Crauwels</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Susan L.</span> <span property="familyName">Ford</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Parul</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vasiliki</span> <span property="familyName">Chounta</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ronald</span> <span property="familyName">D’Amico</span>, <span property="honorificSuffix">D.O.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Simon</span> <span property="familyName">Vanveggel</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Dorey</span>, <span property="honorificSuffix">M.Math.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amy</span> <span property="familyName">Cutrell</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandy</span> <span property="familyName">Griffith</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David A.</span> <span property="familyName">Margolis</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter E.</span> <span property="familyName">Williams</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wim</span> <span property="familyName">Parys</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kimberly Y.</span> <span property="familyName">Smith</span>, <span property="honorificSuffix">M.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">William R.</span> <span property="familyName">Spreen</span>, <span property="honorificSuffix">Pharm.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-19</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 4, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">1124</span>-<span property="pageEnd">1135</span></div><div class="doi">DOI: 10.1056/NEJMoa1909512</div><div class="core-enumeration"><a href="/toc/nejm/382/12"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">12</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DChloe%2BOrkin%252C%2BKeikawus%2BArasteh%252C%2BMiguel%2BG%25C3%25B3rgolas%2BHern%25C3%25A1ndez-Mora%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa1909512%26title%3DLong-Acting%2BCabotegravir%2Band%2BRilpivirine%2Bafter%2BOral%2BInduction%2Bfor%2BHIV-1%2BInfection%26publicationDate%3D03%252F19%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1909512" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DChloe%2BOrkin%252C%2BKeikawus%2BArasteh%252C%2BMiguel%2BG%25C3%25B3rgolas%2BHern%25C3%25A1ndez-Mora%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa1909512%26title%3DLong-Acting%2BCabotegravir%2Band%2BRilpivirine%2Bafter%2BOral%2BInduction%2Bfor%2BHIV-1%2BInfection%26publicationDate%3D03%252F19%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/52d20e9e-8d9f-4b88-85e6-662920fa19ed/nejmoa1909512.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1909512.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1909512" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1909512" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1909512.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir–abacavir–lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm).</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy (adjusted difference, −0.4 percentage points; 95% confidence interval [CI], −2.8 to 2.1), a result that met the criterion for noninferiority for the primary end point (margin, 6 percentage points). An HIV-1 RNA level of less than 50 copies per milliliter at week 48 was found in 93.6% who received long-acting therapy and in 93.3% who received oral therapy (adjusted difference, 0.4 percentage points; 95% CI, −3.7 to 4.5), a result that met the criterion for noninferiority for this end point (margin, −10 percentage points). Of the participants who received long-acting therapy, 86% reported injection-site reactions (median duration, 3 days; mild or moderate severity, 99% of cases); 4 participants withdrew from the trial for injection-related reasons. Grade 3 or higher adverse events and events that met liver-related stopping criteria occurred in 11% and 2%, respectively, who received long-acting therapy and in 4% and 1% who received oral therapy. Treatment satisfaction increased after participants switched to long-acting therapy; 91% preferred long-acting therapy at week 48.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravir–abacavir–lamivudine with regard to maintaining HIV-1 suppression. Injection-site reactions were common. (Funded by ViiV Healthcare and Janssen; FLAIR ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02938520" target="_blank">NCT02938520</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Combination antiretroviral therapy can significantly prolong the life expectancy of people living with human immunodeficiency virus (HIV), but HIV infection remains a chronic condition that requires lifelong daily oral treatment.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Current antiretroviral regimens are highly effective, and one focus of ongoing drug development is improvement of the side-effect profile and convenience to reduce disengagement from care. Prolonged daily regimens can engender dissatisfaction, contribute to stigma, and increase the risk of nonadherence to treatment and treatment failure.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4" href-manipulated="true">3,4</a></sup> Surveys indicate that many patients would prefer therapeutic alternatives.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> Two-drug regimens have been developed as an option<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-1" href-manipulated="true">7,8</a></sup>; long-acting injectable regimens are another alternative that can free patients from the burden of daily regimens and potentially provide a more acceptable therapeutic approach.</div><div role="paragraph">Long-acting injectable formulations are being developed for cabotegravir, which is an integrase strand-transfer inhibitor (INSTI), and rilpivirine, which is a nonnucleoside reverse-transcriptase inhibitor (NNRTI) with an approved oral formulation.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r11" id="body-ref-r11" href-manipulated="true">9-11</a></sup> In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2), participants who had not previously received antiretroviral therapy were given oral cabotegravir-based treatment; those who had viral suppression were randomly assigned to continue oral treatment or switch to monthly intramuscular injections of long-acting cabotegravir plus rilpivirine. Viral suppression was maintained through week 96 in 87% of the participants who switched to monthly long-acting therapy, as compared with 84% of the participants who continued oral therapy<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-1" href-manipulated="true" aria-label="Reference 12">12</a></sup>; viral suppression was maintained through week 160 in 83% of the recipients of long-acting therapy.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup></div><div role="paragraph">The First Long-Acting Injectable Regimen (FLAIR) trial evaluated a potential pathway to long-acting injectable therapy for patients who had not previously received antiretroviral therapy. We assessed whether switching to monthly injections of long-acting cabotegravir plus rilpivirine would be noninferior to continuing oral therapy in patients with HIV type 1 (HIV-1) who had viral suppression in response to oral induction therapy.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Participants</h3><div role="paragraph">We designed this phase 3, randomized, multicenter, open-label, noninferiority trial to have screening, induction, maintenance, extension, and long-term follow-up phases (<a href="#f1">Figure 1A</a>). Eligible participants were 18 years of age or older, had not previously received antiretroviral therapy, and had a plasma HIV-1 RNA level of 1000 copies per milliliter or higher at screening. The complete eligibility criteria are provided in the <a href="#ap2">Supplementary Appendix</a> and the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f1.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/ced5a908-c07e-46b8-bcef-ba4bab38c549/assets/images/large/nejmoa1909512_f1.jpg" height="3438" width="2217" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Trial Design, Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Panel A shows the trial design scheme, which includes screening, induction, maintenance, and extension phases. During the screening phase, adults who met the inclusion criteria were enrolled in the trial; key exclusion criteria were previous use of antiretroviral therapy (ART), detection of hepatitis B virus (HBV) surface antigen, and the presence of nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance mutations other than the K103N mutation. During the induction phase, a single-tablet regimen of dolutegravir, abacavir, and lamivudine (DTG–ABC–3TC) was administered once daily for 20 weeks; those who had side effects in association with this therapy or were positive for HLA-B*5701 received dolutegravir plus two nucleoside reverse-transcriptase inhibitors other than abacavir. During randomization, participants were randomly assigned to continue the current oral therapy or switch to long-acting therapy during the maintenance phase. Participants in the long-acting–therapy group received oral lead-in therapy with cabotegravir (CAB) plus rilpivirine (RPV), followed by injections of long-acting formulations: initial loading injections of 600 mg of cabotegravir and 900 mg of rilpivirine were administered at week 4, and subsequent injections of 400 mg of cabotegravir and 600 mg of rilpivirine were administered every 4 weeks beginning at week 8. In this ongoing trial, participants who discontinue or complete long-acting therapy enter a 52-week long-term follow-up phase. Participants in the oral-therapy group who maintain viral suppression have the option to switch to long-acting therapy during the extension phase. Panel B shows participants who underwent screening, randomization, and treatment. Overall, 566 adults were randomly assigned to treatment; 180 adults who underwent screening were not assigned to treatment, primarily because they did not meet the eligibility requirements (149 participants). Of those 180 participants, 65 were excluded from the trial before randomization, primarily because they did not meet the viral suppression criterion while receiving oral induction therapy; 2 withdrew before receiving induction therapy. Treatment was initiated in 283 participants in each treatment group (intention-to-treat exposed population). The safety and intention-to-treat exposed populations were identical.</div></div></figcaption></figure></div><div role="paragraph">Participants received oral induction therapy with a fixed-dose combination of 50 mg of dolutegravir, 600 mg of abacavir, and 300 mg of lamivudine once daily for 20 weeks; those who had side effects in association with this therapy or were positive for HLA-B*5701 received dolutegravir plus two nucleoside reverse-transcriptase inhibitors other than abacavir. Participants who had a plasma HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks of oral induction therapy were randomly assigned, in a 1:1 ratio, to either continue the current oral therapy during the maintenance phase or switch to long-acting therapy for at least 100 weeks. Participants in the long-acting–therapy group received oral lead-in therapy with 30 mg of cabotegravir and 25 mg of rilpivirine once daily for approximately 4 weeks so that the safety and side-effect profile of the drugs could be confirmed before long-acting injectable therapy was begun. At week 4, the participants received loading injections of 600 mg of cabotegravir and 900 mg of rilpivirine (3 ml each), administered into the gluteus muscle. Subsequent injections of 400 mg of cabotegravir and 600 mg of rilpivirine (2 ml each) were administered within a window of 21 to 28 days after the previous injection for the second and third injections and a window of 21 to 35 days thereafter. Oral bridging therapy with cabotegravir and rilpivirine was available for participants who were unable to attend a visit for injections.</div><div role="paragraph">Participants who had confirmed virologic failure (two consecutive plasma HIV-1 RNA levels ≥200 copies per milliliter) discontinued the assigned treatment. Participants who started long-acting therapy and then discontinued the treatment for any reason entered the 52-week follow-up phase and started an alternative, investigator-selected antiretroviral regimen.</div><div role="paragraph">The trial was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent, and institutional review boards at all sites approved the protocol. The trial funders (ViiV Healthcare and Janssen Research and Development) participated in the design of the trial and in the gathering, analysis, and interpretation of the data. All the authors vouch for the accuracy and completeness of the data and the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Randomization and Masking</h3><div role="paragraph">A randomization sequence generated by GlaxoSmithKline-verified randomization software (RandAll NG, version 1.3.3) was used for treatment assignments, with stratification according to the baseline (preinduction) HIV-1 RNA level (&lt;100,000 or ≥100,000 copies per milliliter) and sex at birth. Central randomization, performed with blocks shared across sites, concealed the treatment schedule to prevent selection bias.</div></section><section id="sec-1-3"><h3>Procedures and End Points</h3><div role="paragraph">Details regarding the trial assessments are provided in the <a href="#ap2">Supplementary Appendix</a>. The primary end point was the percentage of participants who had a plasma HIV-1 RNA level of 50 copies per milliliter or higher at week 48 of the maintenance phase, determined with the use of the Food and Drug Administration (FDA) snapshot algorithm.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> The key secondary end point was the percentage of participants who had a plasma HIV-1 RNA level of less than 50 copies per milliliter at week 48 (FDA snapshot algorithm). Other secondary end points included confirmed virologic failure, genotypic and phenotypic resistance coincident with virologic failure, CD4+ lymphocyte counts, graded adverse events,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> laboratory abnormalities, plasma pharmacokinetics of cabotegravir and rilpivirine, treatment satisfaction scores, adherence to treatment, and virologic outcomes according to randomization strata and baseline subgroups. The baseline subgroups included post hoc subgroups defined according to the presence or absence of the L74I integrase polymorphism and the HIV-1 subtype distribution in each country.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> Treatment satisfaction was measured with the use of the HIV Treatment Satisfaction Questionnaire, change version (HIVTSQc), at week 48.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> The HIVTSQc evaluates participants’ satisfaction with current antiretroviral therapy as compared with induction therapy; total scores range from −33 (much less satisfied now) to 33 (much more satisfied now). In an exploratory analysis, a single-item question regarding preference for long-acting or oral therapy at week 48 was evaluated in the long-acting–therapy group (Table S6 in the <a href="#ap2">Supplementary Appendix</a>). A complete list of trial end points is provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">The primary efficacy analysis included all participants who received at least one dose of the assigned trial drugs during the maintenance phase (intention-to-treat exposed population). For the primary and key secondary efficacy end points, the adjusted difference between treatment groups in the percentage of participants and corresponding 95% confidence intervals were calculated on the basis of a stratified Cochran–Mantel–Haenszel analysis, with adjustment for randomization stratification factors. The primary and key secondary efficacy end points were also assessed in the per-protocol population, which excluded participants who had protocol deviations that were likely to affect efficacy assessments or lead to discontinuation of the trial drugs.</div><div role="paragraph">For the primary end point, noninferiority was concluded if the upper limit of a two-sided 95% confidence interval for the difference between the long-acting–therapy group and the oral-therapy group in the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 was less than 6 percentage points. The noninferiority margin of 6 percentage points was based on clinical considerations that balanced the potential advantages of long-acting therapy over daily oral therapy (e.g., treatment satisfaction and direct observation of treatment administration) with a clinically acceptable virologic failure rate: assuming an observed virologic failure rate in the oral-therapy group of 2%, we determined that noninferiority of long-acting therapy would be shown if the observed difference between treatment groups was less than 3 percentage points. Furthermore, the sample size allows 90% power to assess noninferiority with a more stringent margin of 4 percentage points with the use of pooled data from this trial and the Antiretroviral Therapy as Long Acting Suppression (ATLAS) trial, which involved patients who had previously received antiretroviral therapy.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-1" href-manipulated="true" aria-label="Reference 18">18</a></sup></div><div role="paragraph">Assuming that the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (FDA snapshot algorithm) would be 3% in the long-acting–therapy group and 2% in the oral-therapy group, with a noninferiority margin of 6 percentage points and a one-sided significance level of 2.5%, we calculated that a sample of 285 participants per treatment group would give the trial approximately 97% power to show noninferiority of long-acting therapy to oral therapy with regard to the primary end point. This sample size would also provide more than 94% power to show noninferiority with regard to the key secondary end point, with the assumption of a response rate of 87% with each treatment, a noninferiority margin of −10 percentage points, and a one-sided significance level of 2.5%.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">A total of 809 adults were screened at 108 sites in 11 countries beginning on October 27, 2016 (<a href="#f1">Figure 1B</a>); the last participant completed week 48 on August 30, 2018. Oral induction therapy was initiated in 629 participants; 63 of those participants withdrew from the trial before randomization, primarily because of a lack of efficacy, and the remaining 566 were randomly assigned to treatment in the maintenance phase (283 to each treatment group). During the maintenance phase, 25 participants (9%) in the long-acting–therapy group and 22 participants (8%) in the oral-therapy group withdrew from the trial; withdrawals were most frequently due to adverse events in the long-acting–therapy group (in 9 participants) and participant decision to withdraw in the oral-therapy group (in 7). In the long-acting–therapy group, 98% of the 3577 expected injection visits (12 per participant by week 48, with additional visits beyond week 48) occurred within a window of 21 to 35 days after the previous injection; four of five missed injections were covered with oral bridging therapy (Fig. S1). In the oral-therapy group, adherence to treatment was more than 90% on the basis of patient-reported treatment interruptions of 3 or more consecutive days.</div><div role="paragraph">Across the two treatment groups, participants were a median of 34 years of age, 22% were female, and 74% were white; approximately 20% had an HIV-1 RNA level of 100,000 copies per milliliter or higher at baseline (<a href="#t1">Table 1</a>). Before the induction phase, 69% of the participants had a CD4+ lymphocyte count of 350 per microliter or higher, and this percentage increased to 90% by the start of maintenance therapy.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t1.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/e31513e0-2772-4bea-a85d-df325003c645/assets/images/large/nejmoa1909512_t1.jpg" height="1795" width="1712" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxx-borders">Oral Therapy<br>(N=283)</th><th class="txxr-borders">Total<br>(N=566)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">34 (19–68)</td><td class="xxxx-borders shading">34 (18–68)</td><td class="xxxr-borders shading">34 (18–68)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Age group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;35 yr</td><td class="xxxx-borders shading">143 (51)</td><td class="xxxx-borders shading">145 (51)</td><td class="xxxr-borders shading">288 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">35 to &lt;50 yr</td><td class="xxxx-borders">107 (38)</td><td class="xxxx-borders">109 (39)</td><td class="xxxr-borders">216 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥50 yr</td><td class="xxxx-borders shading">33 (12)</td><td class="xxxx-borders shading">29 (10)</td><td class="xxxr-borders shading">62 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">63 (22)</td><td class="xxxx-borders">64 (23)</td><td class="xxxr-borders">127 (22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">216 (76)</td><td class="xxxx-borders">201 (71)</td><td class="xxxr-borders">417 (74)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">47 (17)</td><td class="xxxx-borders shading">56 (20)</td><td class="xxxr-borders shading">103 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">20 (7)</td><td class="xxxx-borders">24 (8)</td><td class="xxxr-borders">44 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Missing</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">2 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (range)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">24 (17–45)</td><td class="xxxx-borders">24 (13–47)</td><td class="xxxr-borders">24 (13–47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">HIV-1 RNA level — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1000 copies/ml</td><td class="xxxx-borders">9 (3)</td><td class="xxxx-borders">5 (2)</td><td class="xxxr-borders">14 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1000 to &lt;10,000 copies/ml</td><td class="xxxx-borders shading">64 (23)</td><td class="xxxx-borders shading">71 (25)</td><td class="xxxr-borders shading">135 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">10,000 to &lt;50,000 copies/ml</td><td class="xxxx-borders">95 (34)</td><td class="xxxx-borders">113 (40)</td><td class="xxxr-borders">208 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">50,000 to &lt;100,000 copies/ml</td><td class="xxxx-borders shading">59 (21)</td><td class="xxxx-borders shading">38 (13)</td><td class="xxxr-borders shading">97 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">100,000 to &lt;200,000 copies/ml</td><td class="xxxx-borders">30 (11)</td><td class="xxxx-borders">33 (12)</td><td class="xxxr-borders">63 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥200,000 copies/ml</td><td class="xxxx-borders shading">26 (9)</td><td class="xxxx-borders shading">23 (8)</td><td class="xxxr-borders shading">49 (9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">CD4+ lymphocyte count — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;200 per μl</td><td class="xxxx-borders shading">16 (6)</td><td class="xxxx-borders shading">23 (8)</td><td class="xxxr-borders shading">39 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">200 to &lt;350 per μl</td><td class="xxxx-borders">71 (25)</td><td class="xxxx-borders">64 (23)</td><td class="xxxr-borders">135 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">350 to &lt;500 per μl</td><td class="xxxx-borders shading">88 (31)</td><td class="xxxx-borders shading">88 (31)</td><td class="xxxr-borders shading">176 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">≥500 per μl</td><td class="xbxx-borders">108 (38)</td><td class="xbxx-borders">108 (38)</td><td class="xbxr-borders">216 (38)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline, Intention-to-Treat Exposed Population.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 participants (2.1%) who received long-acting therapy and in 7 participants (2.5%) who received oral therapy (adjusted difference, −0.4 percentage points; 95% confidence interval [CI], −2.8 to 2.1), a result that met the prespecified noninferiority criterion for the primary end point (<a href="#t2">Table 2</a>). For this end point, there was no meaningful estimated difference between treatments across subgroups (Fig. S2). Similarly, long-acting therapy was noninferior to oral therapy with regard to the key secondary end point of the percentage of participants with an HIV-1 RNA level of less than 50 copies per milliliter at week 48 (93.6% and 93.3%, respectively; adjusted difference, 0.4 percentage points; 95% CI, −3.7 to 4.5). On tests for evidence against homogeneity in the differences between treatments across randomization strata, results were not significant. All these results were similar in the per-protocol population (<a href="#t2">Table 2</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t2.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/c4b79cbe-5c05-404f-9339-461dabc79560/assets/images/large/nejmoa1909512_t2.jpg" height="1994" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxx-borders">Oral Therapy<br>(N=283)</th><th class="txxx-borders">Difference (95% CI)</th><th class="txxr-borders">Adjusted Difference (95% CI)<a href="#t2fn1" role="doc-noteref">*</a></th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging03">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>percentage points</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Intention-to-treat exposed population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HIV-1 RNA level — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;50 copies/ml</td><td class="xxxx-borders shading">265 (93.6)</td><td class="xxxx-borders shading">264 (93.3)</td><td class="xxxx-borders shading">0.4 (−3.7 to 4.4)</td><td class="xxxr-borders shading">0.4 (−3.7 to 4.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">≥50 copies/ml<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">7 (2.5)</td><td class="xxxx-borders">−0.4 (−2.8 to 2.1)</td><td class="xxxr-borders">−0.4 (−2.8 to 2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Level not below threshold</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Discontinued treatment for lack of efficacy</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Discontinued treatment for other reasons</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No virologic data</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Withdrew from trial owing to adverse event or death</td><td class="xxxx-borders shading">8 (2.8)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Withdrew from trial for other reasons</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">10 (3.5)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Subgroup analysis of HIV-1 RNA level ≥50 copies/ml — no./total no. (%)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Sex at birth</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">3/63 (4.8)</td><td class="xxxx-borders shading">1/64 (1.6)</td><td class="xxxx-borders shading">3.2 (−4.3 to 12.0)</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Male</td><td class="xxxx-borders">3/220 (1.4)</td><td class="xxxx-borders">6/219 (2.7)</td><td class="xxxx-borders">−1.4 (−4.7 to 1.6)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Baseline HIV-1 RNA level</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;100,000 copies/ml</td><td class="xxxx-borders">4/227 (1.8)</td><td class="xxxx-borders">5/227 (2.2)</td><td class="xxxx-borders">−0.4 (−3.6 to 2.5)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥100,000 copies/ml</td><td class="xxxx-borders shading">2/56 (3.6)</td><td class="xxxx-borders shading">2/56 (3.6)</td><td class="xxxx-borders shading">0.0 (−9.2 to 9.2)</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Per-protocol population</b><a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">HIV-1 RNA level — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;50 copies/ml</td><td class="xxxx-borders">260/278 (93.5)</td><td class="xxxx-borders">263/282 (93.3)</td><td class="xxxx-borders">0.3 (−3.9 to 4.4)</td><td class="xxxr-borders">0.3 (−3.8 to 4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">≥50 copies/ml</td><td class="xbxx-borders shading">6/278 (2.2)</td><td class="xbxx-borders shading">7/282 (2.5)</td><td class="xbxx-borders shading">−0.3 (−2.8 to 2.2)</td><td class="xbxr-borders shading">−0.3 (−2.8 to 2.2)</td></tr></tbody></table></div><figcaption><div class="caption">Efficacy Outcomes at Week 48.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Values are based on a stratified Cochran–Mantel–Haenszel analysis, with adjustment for sex at birth and baseline (preinduction) human immunodeficiency virus type 1 (HIV-1) RNA level.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">A level of 50 copies per milliliter or higher was observed at week 48 (level not below threshold) or at the time of treatment discontinuation before week 48.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Separate tests of homogeneity in the differences between treatments across randomization strata were conducted with the use of a weighted least-squares chi-square statistic and a 10% one-sided significance level. The 95% confidence intervals for differences across subgroups were calculated with the use of an unconditional exact method with two inverted one-sided tests.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The per-protocol population excluded 5 participants in the long-acting–therapy group (2 who received treatment outside the permitted window, 2 who had HIV-1 RNA samples that were compromised at the central laboratory, and 1 who received a prohibited HIV-1 medication before the baseline visit) and 1 participant in the oral-therapy group (who received prohibited medications).</div></div></div></figcaption></figure></div><div role="paragraph">In the long-acting–therapy group, 4 participants had confirmed virologic failure. In 1 of those participants (who had HIV-1 subtype AG), oral lead-in therapy was suspended owing to a false-positive pregnancy test; on reinitiation of oral therapy, criteria for confirmed virologic failure were met and the participant was withdrawn from the trial before long-acting therapy was initiated, with no resistance mutations detected. The other 3 participants had NNRTI and INSTI resistance mutations (Table S1) that developed during long-acting therapy; these mutations reduced susceptibility to rilpivirine in 2 participants by a factor of more than 2 and reduced susceptibility to cabotegravir in all 3 participants by a factor of more than 5. These 3 participants had HIV-1 subtype A1 with the L74I integrase polymorphism at baseline. However, 51 of the 54 participants in the long-acting–therapy group who had HIV-1 with the L74I integrase polymorphism at baseline did not have virologic failure (Table S2). In subgroup analyses of the primary end point, no significant difference between treatments was observed in subgroups defined according to the presence or absence of the L74I integrase polymorphism or according to HIV-1 subtype (Fig. S2). In the oral-therapy group, 3 participants had confirmed virologic failure without the development of resistance mutations or phenotypic changes during treatment. In the primary analysis, 2 participants who received long-acting therapy and 4 participants who received oral therapy had an HIV-1 RNA level of 50 copies per milliliter or higher without confirmed virologic failure; neither of the participants who received long-acting therapy had HIV-1 resistance mutations.</div></section><section id="sec-2-3"><h3>Safety and Side Effects</h3><div role="paragraph">During the maintenance phase, the most common adverse events in the long-acting–therapy group, excluding injection-site reactions, were nasopharyngitis, headache, upper respiratory tract infection, and diarrhea (<a href="#t3">Table 3</a> and Table S3). Serious adverse events occurred in 18 participants (6%) who received long-acting therapy and in 12 participants (4%) who received oral therapy (Table S4); each type of event occurred in 1 participant (except hepatitis A, which occurred in 3 participants who received long-acting therapy), with no deaths. Adverse events that led to withdrawal from the trial occurred in 9 participants (3%) who received long-acting therapy and in 4 participants (1%) who received oral therapy. In the long-acting–therapy group, the only events that led to withdrawal in more than 1 participant were viral hepatitis and injection-site pain (in 5 and 2 participants, respectively) (Table S5). During the maintenance phase, events that met liver-related stopping criteria occurred in 7 participants (2%) who received long-acting therapy and in 2 participants (1%) who received oral therapy, including eight cases of acute viral hepatitis and one case of inorganic solvent toxicity. One participant in the oral-therapy group was pregnant and had a healthy baby. At week 48, the median weight gain from baseline was 1.3 kg (interquartile range, −1.0 to 5.0) in the long-acting–therapy group and 1.5 kg (interquartile range, −1.0 to 3.9) in the oral-therapy group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t3.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/200c1502-bc2d-4758-a82c-5c68b138774d/assets/images/large/nejmoa1909512_t3.jpg" height="2493" width="1712" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event Category</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxr-borders">Oral Therapy<br>(N=283)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of participants (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">267 (94)</td><td class="xxxr-borders shading">225 (80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event, excluding injection-site reactions</td><td class="xxxx-borders">246 (87)</td><td class="xxxr-borders">225 (80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade ≥3 adverse events</td><td class="xxxx-borders shading">31 (11)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade ≥3 adverse events, excluding injection-site reactions</td><td class="xxxx-borders">22 (8)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to withdrawal from the trial<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">9 (3)</td><td class="xxxr-borders shading">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse events<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">18 (6)</td><td class="xxxr-borders">12 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to death</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Drug-related adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any</td><td class="xxxx-borders shading">236 (83)</td><td class="xxxr-borders shading">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any, excluding injection-site reactions<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">79 (28)</td><td class="xxxr-borders">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade ≥3</td><td class="xxxx-borders shading">14 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Grade ≥3, excluding injection-site reactions<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Injection-site pain</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any</td><td class="xxxx-borders">227 (80)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade ≥3</td><td class="xxxx-borders shading">11 (4)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events reported in ≥5% of participants in either treatment group, excluding injection-site reactions</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">56 (20)</td><td class="xxxr-borders shading">48 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">39 (14)</td><td class="xxxr-borders">21 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">38 (13)</td><td class="xxxr-borders shading">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">32 (11)</td><td class="xxxr-borders">25 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Influenza</td><td class="xxxx-borders shading">25 (9)</td><td class="xxxr-borders shading">20 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vitamin D deficiency</td><td class="xxxx-borders">23 (8)</td><td class="xxxr-borders">13 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">22 (8)</td><td class="xxxr-borders shading">13 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">22 (8)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hemorrhoids</td><td class="xxxx-borders shading">16 (6)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">16 (6)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">15 (5)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">15 (5)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Pharyngitis</td><td class="xbxx-borders shading">15 (5)</td><td class="xbxr-borders shading">9 (3)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events during the Maintenance Phase.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The most common events that led to withdrawal in the long-acting–therapy group were acute hepatitis B (in 2 participants), hepatitis A (2), and injection-site pain (2); 1 of the participants with hepatitis B had inadequate antibody titers after vaccination. All other adverse events that led to withdrawal were reported in 1 participant each.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">The most common serious adverse event in the long-acting–therapy group was hepatitis A, which was reported in 3 participants, 2 of whom withdrew from the trial. All other serious adverse events were reported in 1 participant each.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Other than injection-site reactions, the most common adverse events that were considered by investigators to be possibly or probably related to long-acting therapy were headache (in 14 participants), pyrexia (13), increased body temperature (8), asthenia (7), and malaise (5). The most common drug-related events in the oral-therapy group were nausea (in 6 participants) and fatigue (5).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">In the long-acting–therapy group, 3 participants had grade 3 events of night sweats, right knee monoarthritis, and poor-quality sleep; 1 participant had a grade 4 elevated lipase level.</div></div></div></figcaption></figure></div><div role="paragraph">Of the participants who received long-acting therapy, 86% had at least one injection-site reaction. The most common injection-site reaction was pain, which was reported by 227 of the 278 participants (82%) who received at least one injection (Table S3). Most of the 1879 pain events were of mild or moderate severity (86% and 13%, respectively); 12 events (&lt;1%) in 11 participants were severe (grade 3), and there were no grade 4 events. The incidence of injection-site reactions was highest (71%) after the initial 3-ml injections at week 4 and subsequently decreased to 20% at week 48 (Fig. S3). The median duration of injection-site reactions was 3 days; 88% of cases resolved within 7 days. Injection-site reactions led to withdrawal from the trial in 2 participants, and another 2 participants withdrew consent for other injection-related reasons. Other adverse events that were considered by investigators to be drug-related were more common with long-acting therapy than with oral therapy (occurring in 28% vs. 10% of the participants). There was no discernible pattern to these events; other than injection-site reactions, the most common drug-related events (occurring in ≥5% of the participants) in the long-acting–therapy group were headache and pyrexia.</div></section><section id="sec-2-4"><h3>Pharmacokinetics</h3><div role="paragraph">Plasma concentrations of cabotegravir and rilpivirine during long-acting therapy (<a href="#f2">Figure 2</a>) were similar to the concentrations reported during oral therapy.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20-1" href-manipulated="true">19,20</a></sup> The geometric mean cabotegravir trough concentration was 1.56 μg per milliliter at week 8 and 3.13 μg per milliliter at week 48; these concentrations are 9.4 times and 18.9 times, respectively, as high as the in vitro protein-adjusted 90% inhibitory concentration (PA-IC<sub>90</sub>) for the drug. The geometric mean rilpivirine trough concentration was 41.2 ng per milliliter at week 8 and 82.4 ng per milliliter at week 48; these concentrations are 3.4 times and 6.9 times as high as the PA-IC<sub>90</sub>. The three participants who received long-acting therapy and had confirmed virologic failure had cabotegravir and rilpivirine concentrations in the lowest quartile, with one having drug concentrations below the fifth percentile (Fig. S4); all three had a body-mass index (the weight in kilograms divided by the square of the height in meters) of more than 30 at baseline, but none missed an injection or received injections outside the permitted window.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f2.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/cb3851ef-7b0a-49d8-866b-d4255b86e7b6/assets/images/large/nejmoa1909512_f2.jpg" height="3197" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Plasma Concentration–Time Profiles.</div><div class="notes"><div role="doc-footnote">Shown are the median plasma concentration–time profiles for cabotegravir (Panel A) and rilpivirine (Panel B) in 278 participants who received monthly injections of long-acting therapy. 𝙸 bars indicate the 5th and 95th percentiles. Dashed lines indicate the in vitro protein-adjusted 90% inhibitory concentration (PA-IC<sub>90</sub>). Predose plasma concentrations are shown.</div></div></figcaption></figure></div></section><section id="sec-2-5"><h3>Patient-Reported Outcomes</h3><div role="paragraph">At week 48, the HIVTSQc total score for satisfaction with current treatment as compared with induction treatment was higher in the long-acting–therapy group than in the oral-therapy group (adjusted mean difference, 4.1 points; 95% CI, 2.8 to 5.5) (Table S7). An exploratory analysis of a single-item question regarding therapy preference at week 48 indicated that 257 of 283 participants (91%) who received long-acting therapy in the intention-to-treat exposed population and 257 of 259 participants (99%) who responded to the survey preferred the long-acting regimen over the previous oral therapy.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The results of this trial show a pathway for patients who have not previously received antiretroviral therapy to reach and maintain HIV-1 suppression with oral induction therapy and a subsequent transition to monthly injectable therapy. After viral suppression was achieved with a standard oral INSTI-based regimen, the simplified injectable regimen, which consisted of long-acting formulations of cabotegravir and rilpivirine, was noninferior to continued oral therapy with regard to maintaining suppression through week 48.</div><div role="paragraph">Baseline viral load had no significant effect on the results for the primary end point; this finding suggests that if the viral load is suppressed without evidence of cabotegravir or rilpivirine resistance mutations, a transition to long-acting therapy is feasible. At baseline, HIV-1 subtype A1 was present in 8 participants in the long-acting–therapy group, 5 of whom maintained viral suppression and 3 of whom had virologic failure. All 3 of the participants who had virologic failure during long-acting therapy also had a body-mass index of more than 30, plasma drug levels in the lowest quartile, and HIV-1 with the L74I integrase polymorphism. However, the L74I integrase polymorphism does not confer resistance to cabotegravir by itself: 51 of 54 participants in the long-acting–therapy group who had the L74I integrase polymorphism did not have virologic failure at week 48.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup> No dosing complications that may have contributed to virologic failure were reported. With virologic failure occurring in only 4 participants in the long-acting–therapy group (and occurring before the initiation of long-acting therapy in 1 of those participants), the potential contributions of virologic, pharmacokinetic, demographic, and other factors to virologic outcomes remain uncertain; future analyses of pooled study data may provide clarification.</div><div role="paragraph">The three-drug combination of dolutegravir, abacavir, and lamivudine that was used for induction therapy and as the control regimen during the maintenance phase is a recommended first-line regimen for patients who have not previously received antiretroviral therapy.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> Efficacy results with long-acting therapy in this trial were similar to those seen in the ATLAS trial, which had a similar switch design but enrolled participants who had longer-term viral suppression, which had been achieved with the use of other standard three-drug oral therapies.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-2" href-manipulated="true" aria-label="Reference 18">18</a></sup> Together, the FLAIR and ATLAS trials show that the long-acting regimen effectively maintained viral suppression that had initially been achieved with the use of oral regimens, both in adults new to treatment and in those who had received prolonged previous treatment.</div><div role="paragraph">Other than injection-site reactions, no patterns of adverse events with the long-acting regimen were evident, a finding consistent with the reported safety profiles of oral cabotegravir and rilpivirine.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r20" id="body-ref-r20-2" href-manipulated="true">12,20</a></sup> Injection-site reactions, primarily pain, were common, but the incidence decreased from 71% to 20% during the trial. Injection-site reactions were generally of mild or moderate severity and transient; 4 of the 283 participants in the long-acting–therapy group withdrew from the trial owing to injection-site reactions or other injection-related reasons. The incidences of some adverse events other than injection-site reactions were higher in the long-acting–therapy group than in the oral-therapy group; however, effects associated with starting a new treatment (as opposed to continuing the same treatment) may have contributed to the observed differences — a possibility consistent with observations in previous switch studies.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r24" id="body-ref-r24" href-manipulated="true">8,24</a></sup></div><div role="paragraph">The long-acting regimen was preferred over the previous oral therapy by 91% of recipients, even after 12 monthly injections. Conclusions derived from this finding are limited to patients who are willing to consider injectable therapy, reflecting the enrolled trial population. Similarly, in clinical practice, the long-acting regimen is a therapeutic option that patients can select according to their preference. For patients who choose long-acting therapy, the data regarding treatment preference suggest that their expectations of regimen benefits will be met.</div><div role="paragraph">The potential clinical role of the long-acting regimen remains to be fully defined for the spectrum of patients with HIV-1 infection, particularly those who have adherence challenges, in different practice settings. In this regard, additional randomized efficacy and safety trials of the long-acting regimen include the ATLAS trial,<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-3" href-manipulated="true" aria-label="Reference 18">18</a></sup> which enrolled participants who had previously received antiretroviral therapy, and the LATITUDE trial (ClinicalTrials.gov number, <a href="https://www.clinicaltrials.gov/ct2/show/NCT03635788" target="_blank">NCT03635788</a>), which enrolled participants who had adherence difficulties. Ongoing follow-up of the FLAIR and ATLAS trials will assess outcomes of long-acting therapy extended beyond 48 weeks. Several additional ongoing or planned studies (e.g., the Cabotegravir plus Rilpivirine in the U.S. to Optimize and Measure Implementation and Experience [CUSTOMIZE] trial; <a href="https://www.clinicaltrials.gov/ct2/show/NCT04001803" target="_blank">NCT04001803</a>) are focused on implementation of the long-acting regimen in various settings, including university hospitals and private and public health clinics.</div><div role="paragraph">In conclusion, monthly two-drug long-acting therapy was noninferior to standard three-drug oral therapy with regard to maintaining viral suppression for 48 weeks in adults with HIV-1 infection who had not previously received antiretroviral therapy, with greater reported treatment satisfaction.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on March 4, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">ViiV Healthcare</span> and <span class="named-content" data-type="funder">Janssen</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the trial participants and their families, the FLAIR clinical investigators and their staff, and trial team members at ViiV Healthcare, GlaxoSmithKline, and Janssen. Editorial assistance with a previous version of the manuscript was provided by Richard Boehme, Ph.D., of Articulate Science and was funded by ViiV Healthcare.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1909512_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1909512/suppl_file/nejmoa1909512_protocol.pdf" download="nejmoa1909512_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1909512_protocol.pdf" data-doi="10.1056/NEJMoa1909512">Download</a></li><li>5.78 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1909512_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1909512/suppl_file/nejmoa1909512_appendix.pdf" download="nejmoa1909512_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1909512_appendix.pdf" data-doi="10.1056/NEJMoa1909512">Download</a></li><li>1.03 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1909512_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1909512/suppl_file/nejmoa1909512_disclosures.pdf" download="nejmoa1909512_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1909512_disclosures.pdf" data-doi="10.1056/NEJMoa1909512">Download</a></li><li>543.38 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1909512_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1909512/suppl_file/nejmoa1909512_data-sharing.pdf" download="nejmoa1909512_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1909512_data-sharing.pdf" data-doi="10.1056/NEJMoa1909512">Download</a></li><li>77.32 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. <em>J Infect Dis</em> 2006;194:11-19.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/505147" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16741877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238337400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+survival+benefits+of+AIDS+treatment+in+the+United+States.&amp;publication_year=2006&amp;journal=J+Infect+Dis&amp;pages=11-19&amp;doi=10.1086%2F505147&amp;pmid=16741877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. <em>N Engl J Med</em> 2011;365:1471-1481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1909512&amp;key=10.1056%2FNEJMoa1013911&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22010913/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296009500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Earlier+versus+later+start+of+antiretroviral+therapy+in+HIV-infected+adults+with+tuberculosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1471-1481&amp;doi=10.1056%2FNEJMoa1013911&amp;pmid=22010913" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Glass T, Cavassini M. Asking about adherence — from flipping the coin to strong evidence. <em>Swiss Med Wkly</em> 2014;144:w14016-w14016.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25275364/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343106100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asking+about+adherence+%E2%80%94+from+flipping+the+coin+to+strong+evidence.&amp;publication_year=2014&amp;journal=Swiss+Med+Wkly&amp;pages=w14016-w14016&amp;pmid=25275364" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. <em>AIDS Behav</em> 2011;15:1381-1396.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10461-011-9942-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21468660/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295271200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adherence+to+highly+active+antiretroviral+therapy+%28HAART%29%3A+a+meta-analysis.&amp;publication_year=2011&amp;journal=AIDS+Behav&amp;pages=1381-1396&amp;doi=10.1007%2Fs10461-011-9942-x&amp;pmid=21468660" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. <em>Nanomedicine (Lond)</em> 2013;8:1807-1813.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2217/nnm.12.214" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23611617/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326034100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+parenteral+nanoformulated+antiretroviral+therapy%3A+interest+and+attitudes+of+HIV-infected+patients.&amp;publication_year=2013&amp;journal=Nanomedicine+%28Lond%29&amp;pages=1807-1813&amp;doi=10.2217%2Fnnm.12.214&amp;pmid=23611617" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Weld ED, Rana MS, Dallas RH, et al. Interest of youth living with HIV in long-acting antiretrovirals. <em>J Acquir Immune Defic Syndr</em> 2019;80:190-197.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0000000000001896" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30418298/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000480761300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interest+of+youth+living+with+HIV+in+long-acting+antiretrovirals.&amp;publication_year=2019&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=190-197&amp;doi=10.1097%2FQAI.0000000000001896&amp;pmid=30418298" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <em>Lancet</em> 2019;393:143-155.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32462-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30420123/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455437100027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dolutegravir+plus+lamivudine+versus+dolutegravir+plus+tenofovir+disoproxil+fumarate+and+emtricitabine+in+antiretroviral-naive+adults+with+HIV-1+infection+%28GEMINI-1+and+GEMINI-2%29%3A+week+48+results+from+two+multicentre%2C+double-blind%2C+randomised%2C+non-inferiority%2C+phase+3+trials.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=143-155&amp;doi=10.1016%2FS0140-6736%2818%2932462-0&amp;pmid=30420123" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <em>Lancet</em> 2018;391:839-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)33095-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29310899/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426463500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+tolerability+of+dolutegravir-rilpivirine+for+the+maintenance+of+virological+suppression+in+adults+with+HIV-1%3A+phase+3%2C+randomised%2C+non-inferiority+SWORD-1+and+SWORD-2+studies.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=839-849&amp;doi=10.1016%2FS0140-6736%2817%2933095-7&amp;pmid=29310899" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens have been developed as an option </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] observations in previous switch studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Odefsey prescribing information. Foster City, CA: Gilead Sciences, 2018 (<a href="https://www.gilead.com/~/media/files/pdfs/medicines/hiv/odefsey/odefsey_pi.pdf?la=en">https://www.gilead.com/~/media/files/pdfs/medicines/hiv/odefsey/odefsey_pi.pdf?la=en</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Odefsey+prescribing+information.&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Karmon SL, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. <em>J Acquir Immune Defic Syndr</em> 2015;68(3):e39-e41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0000000000000469" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25469523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350245400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GSK1265744+demonstrates+robust+in+vitro+activity+against+various+clades+of+HIV-1.&amp;publication_year=2015&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=e39-e41&amp;doi=10.1097%2FQAI.0000000000000469&amp;pmid=25469523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Edurant (rilpivirine) prescribing information. Titusville, NJ: Janssen Therapeutics, 2019 (<a href="http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf">http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Edurant+%28rilpivirine%29+prescribing+information.&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <em>Lancet</em> 2017;390:1499-1510.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)31917-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28750935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411337100025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+intramuscular+cabotegravir+and+rilpivirine+in+adults+with+HIV-1+infection+%28LATTE-2%29%3A+96-week+results+of+a+randomised%2C+open-label%2C+phase+2b%2C+non-inferiority+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=1499-1510&amp;doi=10.1016%2FS0140-6736%2817%2931917-7&amp;pmid=28750935" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the participants who continued oral therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of oral cabotegravir and rilpivirine. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Gonzalez Garcia J, Stellbrink HJ, et al. Safety, efficacy and durability of long-acting cabotegravir (CAB) and rilpivirine (RPV) as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 week 160 results. Presented at HIV Glasgow 2018, Glasgow, Scotland, October 28–31, 2018.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+efficacy+and+durability+of+long-acting+cabotegravir+%28CAB%29+and+rilpivirine+%28RPV%29+as+two-drug+IM+maintenance+therapy+for+HIV-1+infection%3A+LATTE-2+week+160+results." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">FDA Center for Drug Evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. November 2015 (<a href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+immunodeficiency+virus-1+infection%3A+developing+antiretroviral+drugs+for+treatment.+Guidance+for+industry&amp;publication_year=2015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. 2009 (<a href="https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf">https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events%2C+version+1.0.&amp;publication_year=2009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. <em>Lancet Infect Dis</em> 2019;19:143-155.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30647-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30509777/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457299500031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+and+regional+molecular+epidemiology+of+HIV-1%2C+1990-2015%3A+a+systematic+review%2C+global+survey%2C+and+trend+analysis.&amp;publication_year=2019&amp;journal=Lancet+Infect+Dis&amp;pages=143-155&amp;doi=10.1016%2FS1473-3099%2818%2930647-9&amp;pmid=30509777" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Woodcock A, Bradley C. Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ). <em>Qual Life Res</em> 2001;10:517-531.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1023/A:1013050904635" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11789552/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000172453200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+HIV+Treatment+Satisfaction+Questionnaire+%28HIVTSQ%29.&amp;publication_year=2001&amp;journal=Qual+Life+Res&amp;pages=517-531&amp;doi=10.1023%2FA%3A1013050904635&amp;pmid=11789552" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. <em>N Engl J Med</em> 2020;382:1112-1123.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1909512&amp;key=10.1056%2FNEJMoa1904398&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32130809/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521333700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+cabotegravir+and+rilpivirine+for+maintenance+of+HIV-1+suppression.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1112-1123&amp;doi=10.1056%2FNEJMoa1904398&amp;pmid=32130809" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] previously received antiretroviral therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] other standard three-drug oral therapies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] regimen include the ATLAS trial, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Crauwels HM, van Schaick E, Van Heeswijk RP, Vanveggel S, Boven K, Vis P. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naive, HIV-1-infected patients in ECHO and THRIVE. Presented at the 10th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 7–11, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intrinsic+and+extrinsic+factors+on+the+pharmacokinetics+of+TMC278+in+antiretroviral-naive%2C+HIV-1-infected+patients+in+ECHO+and+THRIVE." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. <em>Lancet Infect Dis</em> 2015;15:1145-1155.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(15)00152-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26201299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361854300025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cabotegravir+plus+rilpivirine%2C+once+a+day%2C+after+induction+with+cabotegravir+plus+nucleoside+reverse+transcriptase+inhibitors+in+antiretroviral-naive+adults+with+HIV-1+infection+%28LATTE%29%3A+a+randomised%2C+phase+2b%2C+dose-ranging+trial.&amp;publication_year=2015&amp;journal=Lancet+Infect+Dis&amp;pages=1145-1155&amp;doi=10.1016%2FS1473-3099%2815%2900152-8&amp;pmid=26201299" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reported during oral therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of oral cabotegravir and rilpivirine. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the drug resistance mutations in HIV-1. <em>Top Antivir Med</em> 2016;24:132-133.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28208121/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+Update+of+the+drug+resistance+mutations+in+HIV-1.&amp;publication_year=2016&amp;journal=Top+Antivir+Med&amp;pages=132-133&amp;pmid=28208121" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content"><em>Stanford University HIV Drug Resistance Database</em>. 2019 (<a href="https://hivdb.stanford.edu/">https://hivdb.stanford.edu/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stanford+University+HIV+Drug+Resistance+Database&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: Department of Health and Human Services, 2019 (<a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>.)</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+the+use+of+antiretroviral+agents+in+adults+and+adolescents+with+HIV&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. <em>Trials</em> 2012;13:138-138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1745-6215-13-138" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22906139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311364700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Drug+safety+assessment+in+clinical+trials%3A+methodological+challenges+and+opportunities.&amp;publication_year=2012&amp;journal=Trials&amp;pages=138-138&amp;doi=10.1186%2F1745-6215-13-138&amp;pmid=22906139" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/12"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">12</span></span> • <span property="datePublished">March 19, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1124</span>-<span property="pageEnd">1135</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 4, 2020</div><div><b class="core-label">Published in issue</b>: March 19, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hiv-aids" alt="View article keyword HIV/AIDS" data-interactiontype="article_recirculation_click">HIV/AIDS</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Chloe</span> <span property="familyName">Orkin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Keikawus</span> <span property="familyName">Arasteh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Miguel</span> <span property="familyName">Górgolas Hernández-Mora</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vadim</span> <span property="familyName">Pokrovsky</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Edgar T.</span> <span property="familyName">Overton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pierre-Marie</span> <span property="familyName">Girard</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shinichi</span> <span property="familyName">Oka</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sharon</span> <span property="familyName">Walmsley</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chris</span> <span property="familyName">Bettacchi</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1148-6985" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1148-6985</a></span>, <span property="author" typeof="Person"><span property="givenName">Cynthia</span> <span property="familyName">Brinson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Patrick</span> <span property="familyName">Philibert</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Johan</span> <span property="familyName">Lombaard</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marty</span> <span property="familyName">St. Clair</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Herta</span> <span property="familyName">Crauwels</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Susan L.</span> <span property="familyName">Ford</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Parul</span> <span property="familyName">Patel</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vasiliki</span> <span property="familyName">Chounta</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ronald</span> <span property="familyName">D’Amico</span>, <span property="honorificSuffix">D.O.</span></span>, <span property="author" typeof="Person"><span property="givenName">Simon</span> <span property="familyName">Vanveggel</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Dorey</span>, <span property="honorificSuffix">M.Math.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amy</span> <span property="familyName">Cutrell</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandy</span> <span property="familyName">Griffith</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David A.</span> <span property="familyName">Margolis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter E.</span> <span property="familyName">Williams</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wim</span> <span property="familyName">Parys</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kimberly Y.</span> <span property="familyName">Smith</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">William R.</span> <span property="familyName">Spreen</span>, <span property="honorificSuffix">Pharm.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Queen Mary University of London, London (C.O.), and ViiV Healthcare, Brentford (V.C.) — both in the United Kingdom; EPIMED, Berlin (K.A.); Fundación Jiménez Díaz, Madrid (M.G.H.-M.); Central Research Institute of Epidemiology, Moscow (V.P.); the University of Alabama at Birmingham, Birmingham (E.T.O.); Hôpital Saint Antoine, Paris (P.-M.G.), and Hôpital Européen, Marseille (P. Philibert) — both in France; the National Center for Global Health and Medicine, Tokyo (S.O.); the University Health Network, University of Toronto, Toronto (S.W.), and GlaxoSmithKline, Mississauga (S.L.F., D.D.) — both in Ontario, Canada; North Texas Infectious Disease Consultants, Dallas (C. Bettacchi), and Central Texas Clinical Research, Austin (C. Brinson); Josha Research, Bloemfontein, South Africa (J.L.); ViiV Healthcare, Research Triangle Park, NC (M.S.C., P. Patel, R.D., A.C., S.G., D.A.M., K.Y.S., W.R.S.); and Janssen Research and Development, Beerse, Belgium (H.C., S.V., P.E.W., W.P.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Orkin at Queen Mary University of London, Department of Infection and Immunity, Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom, or at <a href="mailto:c.m.orkin@qmul.ac.uk">c.m.orkin@qmul.ac.uk</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">320</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1909512" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="d50b8b78-762a-2bd6-10d8-8dc5846deb37"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240" style="display:inline-block;">
                <img alt="Article has an altmetric score of 292" src="https://badges.altmetric.com/?size=320&amp;score=292&amp;types=mbcrttwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_d50b8b78-762a-2bd6-10d8-8dc5846deb37" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=news">
          Picked up by <b>32</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=twitter">
          Posted by <b>78</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=wikipedia">
          Referenced in <b>2</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=77052240&amp;tab=guidelines">
          Referenced in <b>2</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>420</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d61dfeb446f1b7-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1909512"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1909512%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="320" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">David Margolis, </li><li class="list-inline-item cited-by__entry__author">Michael Watkins, </li><li class="list-inline-item cited-by__entry__author">Yali Zhu, </li></ul><span class="cited-by__entry__title">Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants, </span><span class="cited-by__entry__series-title">Antimicrobial Agents and Chemotherapy, </span><span class="cited-by__entry__volume"><strong>69</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1128/aac.00200-25" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/aac.00200-25</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/aac.00200-25" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Angela D. Moreland, </li><li class="list-inline-item cited-by__entry__author">Rochelle Hanson, </li><li class="list-inline-item cited-by__entry__author">Stephanie E. Kirk, </li><li class="list-inline-item cited-by__entry__author">Hayley Berry, </li><li class="list-inline-item cited-by__entry__author">Virginia Fonner, </li><li class="list-inline-item cited-by__entry__author">Jamila Williams, </li><li class="list-inline-item cited-by__entry__author">Eric G. Meissner, </li></ul><span class="cited-by__entry__title">Quantitative and Qualitative Perspectives of Participants Who Received Long-Acting Injectable Cabotegravir-Rilpivirine at Home or in Clinic, </span><span class="cited-by__entry__series-title">AIDS Patient Care and STDs, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1089/apc.2025.0024" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1089/apc.2025.0024</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1089/apc.2025.0024" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ishfaq Rashid, </li><li class="list-inline-item cited-by__entry__author">Nathan R. Unger, </li><li class="list-inline-item cited-by__entry__author">Connor Willis, </li><li class="list-inline-item cited-by__entry__author">Teerapon Dhippayom, </li><li class="list-inline-item cited-by__entry__author">Moti Ramgopal, </li><li class="list-inline-item cited-by__entry__author">Elizabeth M. Sherman, </li><li class="list-inline-item cited-by__entry__author">Nicholas Yared, </li><li class="list-inline-item cited-by__entry__author">Rachel Safran, </li><li class="list-inline-item cited-by__entry__author">Edwin Swiatlo, </li><li class="list-inline-item cited-by__entry__author">Amy R. Weinberg, </li><li class="list-inline-item cited-by__entry__author">Soodi Navadeh, </li><li class="list-inline-item cited-by__entry__author">Howard Weston Schmutz, </li><li class="list-inline-item cited-by__entry__author">Nathorn Chaiyakunapruk, </li></ul><span class="cited-by__entry__title">
              Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with
              HIV
              : A systematic literature review and network meta‐analysis
            , </span><span class="cited-by__entry__series-title">HIV Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/hiv.70050" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/hiv.70050</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/hiv.70050" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lauren A.R. Tompkins, </li><li class="list-inline-item cited-by__entry__author">Adrian Khoei, </li><li class="list-inline-item cited-by__entry__author">Oleg Kapeljushnik, </li><li class="list-inline-item cited-by__entry__author">Julie Dumond, </li><li class="list-inline-item cited-by__entry__author">Angela D.M. Kashuba, </li><li class="list-inline-item cited-by__entry__author">Alexander Tropsha, </li><li class="list-inline-item cited-by__entry__author">Robert Hubal, </li><li class="list-inline-item cited-by__entry__author">Mackenzie L. Cottrell, </li></ul><span class="cited-by__entry__title">
                  HIV
              Pharmacology Data Repository: Setting the New Information‐Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies
            , </span><span class="cited-by__entry__series-title">Clinical Pharmacology &amp; Therapeutics, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/cpt.3699" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/cpt.3699</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/cpt.3699" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Carla Osiowy, </li><li class="list-inline-item cited-by__entry__author">Fernando Alvarez, </li><li class="list-inline-item cited-by__entry__author">Carla S. Coffin, </li><li class="list-inline-item cited-by__entry__author">Curtis L. Cooper, </li><li class="list-inline-item cited-by__entry__author">Scott K. Fung, </li><li class="list-inline-item cited-by__entry__author">Hin Hin Ko, </li><li class="list-inline-item cited-by__entry__author">Sébastien Poulin, </li><li class="list-inline-item cited-by__entry__author">Jennifer van Gennip, </li></ul><span class="cited-by__entry__title">La prise en charge de l'hépatite B chronique: mise à jour 2025 des lignes directrices de l'Association canadienne pour l'étude du foie et de l'Association pour la microbiologie médicale et l'infectiologie Canada, </span><span class="cited-by__entry__series-title">Canadian Liver Journal, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(402-440), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3138/canlivj-2025-0012-f" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3138/canlivj-2025-0012-f</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3138/canlivj-2025-0012-f" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Carla Osiowy, </li><li class="list-inline-item cited-by__entry__author">Fernando Alvarez, </li><li class="list-inline-item cited-by__entry__author">Carla S Coffin, </li><li class="list-inline-item cited-by__entry__author">Curtis L Cooper, </li><li class="list-inline-item cited-by__entry__author">Scott K Fung, </li><li class="list-inline-item cited-by__entry__author">Hin Hin Ko, </li><li class="list-inline-item cited-by__entry__author">Sébastien Poulin, </li><li class="list-inline-item cited-by__entry__author">Jennifer van Gennip, </li></ul><span class="cited-by__entry__title">The management of chronic hepatitis B: 2025 Guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada, </span><span class="cited-by__entry__series-title">Canadian Liver Journal, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(368-401), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3138/canlivj-2025-0012-e" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3138/canlivj-2025-0012-e</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3138/canlivj-2025-0012-e" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kelong Han, </li><li class="list-inline-item cited-by__entry__author">Paul Benn, </li><li class="list-inline-item cited-by__entry__author">Jörg Sievers, </li><li class="list-inline-item cited-by__entry__author">David Dorey, </li><li class="list-inline-item cited-by__entry__author">Michael Warwick‐Sanders, </li><li class="list-inline-item cited-by__entry__author">Randa Hareedy, </li><li class="list-inline-item cited-by__entry__author">Louise Harkness, </li><li class="list-inline-item cited-by__entry__author">Claudia Leemereise, </li><li class="list-inline-item cited-by__entry__author">Kjersten Offenbecker, </li><li class="list-inline-item cited-by__entry__author">Christina Donatti, </li><li class="list-inline-item cited-by__entry__author">Darin B. Brimhall, </li><li class="list-inline-item cited-by__entry__author">Christian Schwabe, </li><li class="list-inline-item cited-by__entry__author">Craig Boyle, </li><li class="list-inline-item cited-by__entry__author">Michael A. Hassman, </li><li class="list-inline-item cited-by__entry__author">Steve Knowles, </li><li class="list-inline-item cited-by__entry__author">Ronald D'Amico, </li><li class="list-inline-item cited-by__entry__author">William R. Spreen, </li></ul><span class="cited-by__entry__title">A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV, </span><span class="cited-by__entry__series-title">Clinical Pharmacology in Drug Development, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/cpdd.1538" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/cpdd.1538</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/cpdd.1538" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Andrea De Vito, </li><li class="list-inline-item cited-by__entry__author">Alessandro Tavelli, </li><li class="list-inline-item cited-by__entry__author">Alessandro Cozzi‐Lepri, </li><li class="list-inline-item cited-by__entry__author">Andrea Giacomelli, </li><li class="list-inline-item cited-by__entry__author">Roberto Rossotti, </li><li class="list-inline-item cited-by__entry__author">Giacomo Ponta, </li><li class="list-inline-item cited-by__entry__author">Nicoletta Bobbio, </li><li class="list-inline-item cited-by__entry__author">Alice Ianniello, </li><li class="list-inline-item cited-by__entry__author">Antonella Cingolani, </li><li class="list-inline-item cited-by__entry__author">Giordano Madeddu, </li><li class="list-inline-item cited-by__entry__author">Andrea Antinori, </li><li class="list-inline-item cited-by__entry__author">Antonella d'Arminio Monforte, </li></ul><span class="cited-by__entry__title">
              Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with
              HIV
              : Insights from the Icona cohort
            , </span><span class="cited-by__entry__series-title">HIV Medicine, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(970-977), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/hiv.70037" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/hiv.70037</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/hiv.70037" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shawnalyn W. Sunagawa, </li><li class="list-inline-item cited-by__entry__author">Kimberly K. Scarsi, </li></ul><span class="cited-by__entry__title">A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy, </span><span class="cited-by__entry__series-title">Expert Opinion on Pharmacotherapy, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">8, </span><span class="cited-by__entry__page-range">(961-968), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14656566.2025.2499151" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14656566.2025.2499151</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14656566.2025.2499151" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nilay Thakkar, </li><li class="list-inline-item cited-by__entry__author">Rulan Griesel, </li><li class="list-inline-item cited-by__entry__author">Amy Pierce, </li><li class="list-inline-item cited-by__entry__author">Veronica Bainbridge, </li><li class="list-inline-item cited-by__entry__author">Bronagh Shepherd, </li><li class="list-inline-item cited-by__entry__author">Konstantinos Angelis, </li><li class="list-inline-item cited-by__entry__author">Andrew Tomlinson, </li><li class="list-inline-item cited-by__entry__author">Yash Gandhi, </li><li class="list-inline-item cited-by__entry__author">Darin Brimhall, </li><li class="list-inline-item cited-by__entry__author">Daijha Anderson, </li><li class="list-inline-item cited-by__entry__author">Susan Andrews, </li><li class="list-inline-item cited-by__entry__author">Carolina Acuipil, </li><li class="list-inline-item cited-by__entry__author">Cynthia McCoig, </li><li class="list-inline-item cited-by__entry__author">Mark Baker, </li><li class="list-inline-item cited-by__entry__author">Paul Benn, </li></ul><span class="cited-by__entry__title">Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV, </span><span class="cited-by__entry__series-title">Infectious Diseases and Therapy, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40121-025-01154-x" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40121-025-01154-x</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40121-025-01154-x" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1909512%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1909512" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1909512" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1909512.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f1.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/ced5a908-c07e-46b8-bcef-ba4bab38c549/assets/images/large/nejmoa1909512_f1.jpg" height="3438" width="2217" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Trial Design, Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Panel A shows the trial design scheme, which includes screening, induction, maintenance, and extension phases. During the screening phase, adults who met the inclusion criteria were enrolled in the trial; key exclusion criteria were previous use of antiretroviral therapy (ART), detection of hepatitis B virus (HBV) surface antigen, and the presence of nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance mutations other than the K103N mutation. During the induction phase, a single-tablet regimen of dolutegravir, abacavir, and lamivudine (DTG–ABC–3TC) was administered once daily for 20 weeks; those who had side effects in association with this therapy or were positive for HLA-B*5701 received dolutegravir plus two nucleoside reverse-transcriptase inhibitors other than abacavir. During randomization, participants were randomly assigned to continue the current oral therapy or switch to long-acting therapy during the maintenance phase. Participants in the long-acting–therapy group received oral lead-in therapy with cabotegravir (CAB) plus rilpivirine (RPV), followed by injections of long-acting formulations: initial loading injections of 600 mg of cabotegravir and 900 mg of rilpivirine were administered at week 4, and subsequent injections of 400 mg of cabotegravir and 600 mg of rilpivirine were administered every 4 weeks beginning at week 8. In this ongoing trial, participants who discontinue or complete long-acting therapy enter a 52-week long-term follow-up phase. Participants in the oral-therapy group who maintain viral suppression have the option to switch to long-acting therapy during the extension phase. Panel B shows participants who underwent screening, randomization, and treatment. Overall, 566 adults were randomly assigned to treatment; 180 adults who underwent screening were not assigned to treatment, primarily because they did not meet the eligibility requirements (149 participants). Of those 180 participants, 65 were excluded from the trial before randomization, primarily because they did not meet the viral suppression criterion while receiving oral induction therapy; 2 withdrew before receiving induction therapy. Treatment was initiated in 283 participants in each treatment group (intention-to-treat exposed population). The safety and intention-to-treat exposed populations were identical.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f2.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/cb3851ef-7b0a-49d8-866b-d4255b86e7b6/assets/images/large/nejmoa1909512_f2.jpg" height="3197" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Plasma Concentration–Time Profiles.</div><div class="notes"><div role="doc-footnote">Shown are the median plasma concentration–time profiles for cabotegravir (Panel A) and rilpivirine (Panel B) in 278 participants who received monthly injections of long-acting therapy. 𝙸 bars indicate the 5th and 95th percentiles. Dashed lines indicate the in vitro protein-adjusted 90% inhibitory concentration (PA-IC<sub>90</sub>). Predose plasma concentrations are shown.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1909512/asset/e31513e0-2772-4bea-a85d-df325003c645/assets/images/large/nejmoa1909512_t1.jpg" height="1795" width="1712" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxx-borders">Oral Therapy<br>(N=283)</th><th class="txxr-borders">Total<br>(N=566)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">34 (19–68)</td><td class="xxxx-borders shading">34 (18–68)</td><td class="xxxr-borders shading">34 (18–68)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Age group — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;35 yr</td><td class="xxxx-borders shading">143 (51)</td><td class="xxxx-borders shading">145 (51)</td><td class="xxxr-borders shading">288 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">35 to &lt;50 yr</td><td class="xxxx-borders">107 (38)</td><td class="xxxx-borders">109 (39)</td><td class="xxxr-borders">216 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥50 yr</td><td class="xxxx-borders shading">33 (12)</td><td class="xxxx-borders shading">29 (10)</td><td class="xxxr-borders shading">62 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">63 (22)</td><td class="xxxx-borders">64 (23)</td><td class="xxxr-borders">127 (22)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">216 (76)</td><td class="xxxx-borders">201 (71)</td><td class="xxxr-borders">417 (74)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">47 (17)</td><td class="xxxx-borders shading">56 (20)</td><td class="xxxr-borders shading">103 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">20 (7)</td><td class="xxxx-borders">24 (8)</td><td class="xxxr-borders">44 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Missing</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">2 (&lt;1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (range)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">24 (17–45)</td><td class="xxxx-borders">24 (13–47)</td><td class="xxxr-borders">24 (13–47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">HIV-1 RNA level — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">&lt;1000 copies/ml</td><td class="xxxx-borders">9 (3)</td><td class="xxxx-borders">5 (2)</td><td class="xxxr-borders">14 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1000 to &lt;10,000 copies/ml</td><td class="xxxx-borders shading">64 (23)</td><td class="xxxx-borders shading">71 (25)</td><td class="xxxr-borders shading">135 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">10,000 to &lt;50,000 copies/ml</td><td class="xxxx-borders">95 (34)</td><td class="xxxx-borders">113 (40)</td><td class="xxxr-borders">208 (37)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">50,000 to &lt;100,000 copies/ml</td><td class="xxxx-borders shading">59 (21)</td><td class="xxxx-borders shading">38 (13)</td><td class="xxxr-borders shading">97 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">100,000 to &lt;200,000 copies/ml</td><td class="xxxx-borders">30 (11)</td><td class="xxxx-borders">33 (12)</td><td class="xxxr-borders">63 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥200,000 copies/ml</td><td class="xxxx-borders shading">26 (9)</td><td class="xxxx-borders shading">23 (8)</td><td class="xxxr-borders shading">49 (9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">CD4+ lymphocyte count — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;200 per μl</td><td class="xxxx-borders shading">16 (6)</td><td class="xxxx-borders shading">23 (8)</td><td class="xxxr-borders shading">39 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">200 to &lt;350 per μl</td><td class="xxxx-borders">71 (25)</td><td class="xxxx-borders">64 (23)</td><td class="xxxr-borders">135 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">350 to &lt;500 per μl</td><td class="xxxx-borders shading">88 (31)</td><td class="xxxx-borders shading">88 (31)</td><td class="xxxr-borders shading">176 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">≥500 per μl</td><td class="xbxx-borders">108 (38)</td><td class="xbxx-borders">108 (38)</td><td class="xbxr-borders">216 (38)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the participant.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline, Intention-to-Treat Exposed Population.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1909512/asset/c4b79cbe-5c05-404f-9339-461dabc79560/assets/images/large/nejmoa1909512_t2.jpg" height="1994" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxx-borders">Oral Therapy<br>(N=283)</th><th class="txxx-borders">Difference (95% CI)</th><th class="txxr-borders">Adjusted Difference (95% CI)<a href="#core-t2fn1" role="doc-noteref">*</a></th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging03">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>percentage points</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Intention-to-treat exposed population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">HIV-1 RNA level — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">&lt;50 copies/ml</td><td class="xxxx-borders shading">265 (93.6)</td><td class="xxxx-borders shading">264 (93.3)</td><td class="xxxx-borders shading">0.4 (−3.7 to 4.4)</td><td class="xxxr-borders shading">0.4 (−3.7 to 4.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">≥50 copies/ml<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">7 (2.5)</td><td class="xxxx-borders">−0.4 (−2.8 to 2.1)</td><td class="xxxr-borders">−0.4 (−2.8 to 2.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Level not below threshold</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Discontinued treatment for lack of efficacy</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Discontinued treatment for other reasons</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No virologic data</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Withdrew from trial owing to adverse event or death</td><td class="xxxx-borders shading">8 (2.8)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Withdrew from trial for other reasons</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">10 (3.5)</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Subgroup analysis of HIV-1 RNA level ≥50 copies/ml — no./total no. (%)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Sex at birth</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Female</td><td class="xxxx-borders shading">3/63 (4.8)</td><td class="xxxx-borders shading">1/64 (1.6)</td><td class="xxxx-borders shading">3.2 (−4.3 to 12.0)</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Male</td><td class="xxxx-borders">3/220 (1.4)</td><td class="xxxx-borders">6/219 (2.7)</td><td class="xxxx-borders">−1.4 (−4.7 to 1.6)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Baseline HIV-1 RNA level</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;100,000 copies/ml</td><td class="xxxx-borders">4/227 (1.8)</td><td class="xxxx-borders">5/227 (2.2)</td><td class="xxxx-borders">−0.4 (−3.6 to 2.5)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥100,000 copies/ml</td><td class="xxxx-borders shading">2/56 (3.6)</td><td class="xxxx-borders shading">2/56 (3.6)</td><td class="xxxx-borders shading">0.0 (−9.2 to 9.2)</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Per-protocol population</b><a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">HIV-1 RNA level — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&lt;50 copies/ml</td><td class="xxxx-borders">260/278 (93.5)</td><td class="xxxx-borders">263/282 (93.3)</td><td class="xxxx-borders">0.3 (−3.9 to 4.4)</td><td class="xxxr-borders">0.3 (−3.8 to 4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">≥50 copies/ml</td><td class="xbxx-borders shading">6/278 (2.2)</td><td class="xbxx-borders shading">7/282 (2.5)</td><td class="xbxx-borders shading">−0.3 (−2.8 to 2.2)</td><td class="xbxr-borders shading">−0.3 (−2.8 to 2.2)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Values are based on a stratified Cochran–Mantel–Haenszel analysis, with adjustment for sex at birth and baseline (preinduction) human immunodeficiency virus type 1 (HIV-1) RNA level.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">A level of 50 copies per milliliter or higher was observed at week 48 (level not below threshold) or at the time of treatment discontinuation before week 48.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Separate tests of homogeneity in the differences between treatments across randomization strata were conducted with the use of a weighted least-squares chi-square statistic and a 10% one-sided significance level. The 95% confidence intervals for differences across subgroups were calculated with the use of an unconditional exact method with two inverted one-sided tests.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The per-protocol population excluded 5 participants in the long-acting–therapy group (2 who received treatment outside the permitted window, 2 who had HIV-1 RNA samples that were compromised at the central laboratory, and 1 who received a prohibited HIV-1 medication before the baseline visit) and 1 participant in the oral-therapy group (who received prohibited medications).</div></div></div></figcaption></a><figcaption><div class="caption">Efficacy Outcomes at Week 48.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1909512/asset/200c1502-bc2d-4758-a82c-5c68b138774d/assets/images/large/nejmoa1909512_t3.jpg" height="2493" width="1712" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event Category</th><th class="txxx-borders">Long-Acting Therapy<br>(N=283)</th><th class="txxr-borders">Oral Therapy<br>(N=283)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="2"><span>number of participants (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">267 (94)</td><td class="xxxr-borders shading">225 (80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any adverse event, excluding injection-site reactions</td><td class="xxxx-borders">246 (87)</td><td class="xxxr-borders">225 (80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Grade ≥3 adverse events</td><td class="xxxx-borders shading">31 (11)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Grade ≥3 adverse events, excluding injection-site reactions</td><td class="xxxx-borders">22 (8)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to withdrawal from the trial<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">9 (3)</td><td class="xxxr-borders shading">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse events<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">18 (6)</td><td class="xxxr-borders">12 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events that led to death</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Drug-related adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Any</td><td class="xxxx-borders shading">236 (83)</td><td class="xxxr-borders shading">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any, excluding injection-site reactions<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">79 (28)</td><td class="xxxr-borders">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade ≥3</td><td class="xxxx-borders shading">14 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Grade ≥3, excluding injection-site reactions<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">4 (1)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Injection-site pain</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Any</td><td class="xxxx-borders">227 (80)</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Grade ≥3</td><td class="xxxx-borders shading">11 (4)</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events reported in ≥5% of participants in either treatment group, excluding injection-site reactions</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">56 (20)</td><td class="xxxr-borders shading">48 (17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Headache</td><td class="xxxx-borders">39 (14)</td><td class="xxxr-borders">21 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">38 (13)</td><td class="xxxr-borders shading">28 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">32 (11)</td><td class="xxxr-borders">25 (9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Influenza</td><td class="xxxx-borders shading">25 (9)</td><td class="xxxr-borders shading">20 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Vitamin D deficiency</td><td class="xxxx-borders">23 (8)</td><td class="xxxr-borders">13 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">22 (8)</td><td class="xxxr-borders shading">13 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">22 (8)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hemorrhoids</td><td class="xxxx-borders shading">16 (6)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nausea</td><td class="xxxx-borders">16 (6)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">15 (5)</td><td class="xxxr-borders shading">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">15 (5)</td><td class="xxxr-borders">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Pharyngitis</td><td class="xbxx-borders shading">15 (5)</td><td class="xbxr-borders shading">9 (3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The most common events that led to withdrawal in the long-acting–therapy group were acute hepatitis B (in 2 participants), hepatitis A (2), and injection-site pain (2); 1 of the participants with hepatitis B had inadequate antibody titers after vaccination. All other adverse events that led to withdrawal were reported in 1 participant each.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The most common serious adverse event in the long-acting–therapy group was hepatitis A, which was reported in 3 participants, 2 of whom withdrew from the trial. All other serious adverse events were reported in 1 participant each.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Other than injection-site reactions, the most common adverse events that were considered by investigators to be possibly or probably related to long-acting therapy were headache (in 14 participants), pyrexia (13), increased body temperature (8), asthenia (7), and malaise (5). The most common drug-related events in the oral-therapy group were nausea (in 6 participants) and fatigue (5).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">In the long-acting–therapy group, 3 participants had grade 3 events of night sweats, right knee monoarthritis, and poor-quality sleep; 1 participant had a grade 4 elevated lipase level.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events during the Maintenance Phase.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1909512_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1909512</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. <em>J Infect Dis</em> 2006;194:11-19.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1086/505147" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16741877/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000238337400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+survival+benefits+of+AIDS+treatment+in+the+United+States.&amp;publication_year=2006&amp;journal=J+Infect+Dis&amp;pages=11-19&amp;doi=10.1086%2F505147&amp;pmid=16741877" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. <em>N Engl J Med</em> 2011;365:1471-1481.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_3_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1909512&amp;key=10.1056%2FNEJMoa1013911&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22010913/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000296009500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Earlier+versus+later+start+of+antiretroviral+therapy+in+HIV-infected+adults+with+tuberculosis.&amp;publication_year=2011&amp;journal=N+Engl+J+Med&amp;pages=1471-1481&amp;doi=10.1056%2FNEJMoa1013911&amp;pmid=22010913" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Glass T, Cavassini M. Asking about adherence — from flipping the coin to strong evidence. <em>Swiss Med Wkly</em> 2014;144:w14016-w14016.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25275364/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343106100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asking+about+adherence+%E2%80%94+from+flipping+the+coin+to+strong+evidence.&amp;publication_year=2014&amp;journal=Swiss+Med+Wkly&amp;pages=w14016-w14016&amp;pmid=25275364" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. <em>AIDS Behav</em> 2011;15:1381-1396.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10461-011-9942-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21468660/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295271200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adherence+to+highly+active+antiretroviral+therapy+%28HAART%29%3A+a+meta-analysis.&amp;publication_year=2011&amp;journal=AIDS+Behav&amp;pages=1381-1396&amp;doi=10.1007%2Fs10461-011-9942-x&amp;pmid=21468660" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Williams J, Sayles HR, Meza JL, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. <em>Nanomedicine (Lond)</em> 2013;8:1807-1813.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2217/nnm.12.214" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23611617/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000326034100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+parenteral+nanoformulated+antiretroviral+therapy%3A+interest+and+attitudes+of+HIV-infected+patients.&amp;publication_year=2013&amp;journal=Nanomedicine+%28Lond%29&amp;pages=1807-1813&amp;doi=10.2217%2Fnnm.12.214&amp;pmid=23611617" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Weld ED, Rana MS, Dallas RH, et al. Interest of youth living with HIV in long-acting antiretrovirals. <em>J Acquir Immune Defic Syndr</em> 2019;80:190-197.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0000000000001896" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30418298/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000480761300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interest+of+youth+living+with+HIV+in+long-acting+antiretrovirals.&amp;publication_year=2019&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=190-197&amp;doi=10.1097%2FQAI.0000000000001896&amp;pmid=30418298" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <em>Lancet</em> 2019;393:143-155.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32462-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30420123/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455437100027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dolutegravir+plus+lamivudine+versus+dolutegravir+plus+tenofovir+disoproxil+fumarate+and+emtricitabine+in+antiretroviral-naive+adults+with+HIV-1+infection+%28GEMINI-1+and+GEMINI-2%29%3A+week+48+results+from+two+multicentre%2C+double-blind%2C+randomised%2C+non-inferiority%2C+phase+3+trials.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=143-155&amp;doi=10.1016%2FS0140-6736%2818%2932462-0&amp;pmid=30420123" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. <em>Lancet</em> 2018;391:839-849.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)33095-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29310899/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000426463500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy%2C+safety%2C+and+tolerability+of+dolutegravir-rilpivirine+for+the+maintenance+of+virological+suppression+in+adults+with+HIV-1%3A+phase+3%2C+randomised%2C+non-inferiority+SWORD-1+and+SWORD-2+studies.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=839-849&amp;doi=10.1016%2FS0140-6736%2817%2933095-7&amp;pmid=29310899" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens have been developed as an option </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] observations in previous switch studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Odefsey prescribing information. Foster City, CA: Gilead Sciences, 2018 (<a href="https://www.gilead.com/~/media/files/pdfs/medicines/hiv/odefsey/odefsey_pi.pdf?la=en">https://www.gilead.com/~/media/files/pdfs/medicines/hiv/odefsey/odefsey_pi.pdf?la=en</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Odefsey+prescribing+information.&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Karmon SL, Mohri H, Spreen W, Markowitz M. GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. <em>J Acquir Immune Defic Syndr</em> 2015;68(3):e39-e41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/QAI.0000000000000469" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25469523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350245400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GSK1265744+demonstrates+robust+in+vitro+activity+against+various+clades+of+HIV-1.&amp;publication_year=2015&amp;journal=J+Acquir+Immune+Defic+Syndr&amp;pages=e39-e41&amp;doi=10.1097%2FQAI.0000000000000469&amp;pmid=25469523" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Edurant (rilpivirine) prescribing information. Titusville, NJ: Janssen Therapeutics, 2019 (<a href="http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf">http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Edurant+%28rilpivirine%29+prescribing+information.&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. <em>Lancet</em> 2017;390:1499-1510.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)31917-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28750935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411337100025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+intramuscular+cabotegravir+and+rilpivirine+in+adults+with+HIV-1+infection+%28LATTE-2%29%3A+96-week+results+of+a+randomised%2C+open-label%2C+phase+2b%2C+non-inferiority+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=1499-1510&amp;doi=10.1016%2FS0140-6736%2817%2931917-7&amp;pmid=28750935" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the participants who continued oral therapy </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of oral cabotegravir and rilpivirine. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Gonzalez Garcia J, Stellbrink HJ, et al. Safety, efficacy and durability of long-acting cabotegravir (CAB) and rilpivirine (RPV) as two-drug IM maintenance therapy for HIV-1 infection: LATTE-2 week 160 results. Presented at HIV Glasgow 2018, Glasgow, Scotland, October 28–31, 2018.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+efficacy+and+durability+of+long-acting+cabotegravir+%28CAB%29+and+rilpivirine+%28RPV%29+as+two-drug+IM+maintenance+therapy+for+HIV-1+infection%3A+LATTE-2+week+160+results." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">FDA Center for Drug Evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. November 2015 (<a href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Human+immunodeficiency+virus-1+infection%3A+developing+antiretroviral+drugs+for+treatment.+Guidance+for+industry&amp;publication_year=2015" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">National Institutes of Health. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. 2009 (<a href="https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf">https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Division+of+AIDS+table+for+grading+the+severity+of+adult+and+pediatric+adverse+events%2C+version+1.0.&amp;publication_year=2009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. <em>Lancet Infect Dis</em> 2019;19:143-155.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30647-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30509777/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457299500031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+and+regional+molecular+epidemiology+of+HIV-1%2C+1990-2015%3A+a+systematic+review%2C+global+survey%2C+and+trend+analysis.&amp;publication_year=2019&amp;journal=Lancet+Infect+Dis&amp;pages=143-155&amp;doi=10.1016%2FS1473-3099%2818%2930647-9&amp;pmid=30509777" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Woodcock A, Bradley C. Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ). <em>Qual Life Res</em> 2001;10:517-531.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1023/A:1013050904635" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11789552/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000172453200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+HIV+Treatment+Satisfaction+Questionnaire+%28HIVTSQ%29.&amp;publication_year=2001&amp;journal=Qual+Life+Res&amp;pages=517-531&amp;doi=10.1023%2FA%3A1013050904635&amp;pmid=11789552" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. <em>N Engl J Med</em> 2020;382:1112-1123.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1909512&amp;key=10.1056%2FNEJMoa1904398&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32130809/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521333700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-acting+cabotegravir+and+rilpivirine+for+maintenance+of+HIV-1+suppression.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1112-1123&amp;doi=10.1056%2FNEJMoa1904398&amp;pmid=32130809" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] previously received antiretroviral therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] other standard three-drug oral therapies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] regimen include the ATLAS trial, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Crauwels HM, van Schaick E, Van Heeswijk RP, Vanveggel S, Boven K, Vis P. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naive, HIV-1-infected patients in ECHO and THRIVE. Presented at the 10th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 7–11, 2010.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intrinsic+and+extrinsic+factors+on+the+pharmacokinetics+of+TMC278+in+antiretroviral-naive%2C+HIV-1-infected+patients+in+ECHO+and+THRIVE." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. <em>Lancet Infect Dis</em> 2015;15:1145-1155.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(15)00152-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26201299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361854300025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cabotegravir+plus+rilpivirine%2C+once+a+day%2C+after+induction+with+cabotegravir+plus+nucleoside+reverse+transcriptase+inhibitors+in+antiretroviral-naive+adults+with+HIV-1+infection+%28LATTE%29%3A+a+randomised%2C+phase+2b%2C+dose-ranging+trial.&amp;publication_year=2015&amp;journal=Lancet+Infect+Dis&amp;pages=1145-1155&amp;doi=10.1016%2FS1473-3099%2815%2900152-8&amp;pmid=26201299" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] reported during oral therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of oral cabotegravir and rilpivirine. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Wensing AM, Calvez V, Günthard HF, et al. 2017 Update of the drug resistance mutations in HIV-1. <em>Top Antivir Med</em> 2016;24:132-133.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28208121/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2017+Update+of+the+drug+resistance+mutations+in+HIV-1.&amp;publication_year=2016&amp;journal=Top+Antivir+Med&amp;pages=132-133&amp;pmid=28208121" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content"><em>Stanford University HIV Drug Resistance Database</em>. 2019 (<a href="https://hivdb.stanford.edu/">https://hivdb.stanford.edu/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stanford+University+HIV+Drug+Resistance+Database&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: Department of Health and Human Services, 2019 (<a href="http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>.)</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+the+use+of+antiretroviral+agents+in+adults+and+adolescents+with+HIV&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. <em>Trials</em> 2012;13:138-138.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1745-6215-13-138" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22906139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000311364700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Drug+safety+assessment+in+clinical+trials%3A+methodological+challenges+and+opportunities.&amp;publication_year=2012&amp;journal=Trials&amp;pages=138-138&amp;doi=10.1186%2F1745-6215-13-138&amp;pmid=22906139" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2002199" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Monthly Injectable Antiretroviral Therapy — Version 1.0 of a New Treatment Approach</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.S. Currier</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 04, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1904398" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S. Swindells and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/872568/musculoskeletal-radiologist-suffolk-county-and-nassau-county-ny/?query=fjwp&amp;rid=3059">Musculoskeletal Radiologist, Suffolk County and Nassau County, NY</a></div></div><div class="nejm-widget_item"><div><span> New Hyde Park, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/766578/division-chief-neuroanesthesia-northwell-health-new-hyde-park-new-york/?query=fjwp&amp;rid=3059">Division Chief, Neuroanesthesia Northwell Health - New Hyde Park, New York</a></div></div><div class="nejm-widget_item"><div><span> Billings, Montana</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877579/family-medicine-physician-west-grand/?query=fjwf&amp;rid=751">Family Medicine Physician West Grand</a></div></div><div class="nejm-widget_item"><div><span> Virginia</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883619/general-anesthesia-opening-short-drive-to-dc-600k-income-package/?query=fjwf&amp;rid=5263">General Anesthesia Opening- Short drive to DC-$600K+ income package</a></div></div><div class="nejm-widget_item"><div><span> Lutz, Florida</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891219/neonatologist/?query=fjwf&amp;rid=49812">Neonatologist</a></div></div><div class="nejm-widget_item"><div><span> West Warwick, Rhode Island</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888381/adult-psychiatrist/?query=fjwf&amp;rid=377088">Adult Psychiatrist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1909512&amp;pubId=41288603&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d61dfeb446f1b7-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d61dfeb446f1b7-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d61dfeb446f1b7-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$640821808$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$640821808$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$640821808$--></div></div><div class="mlt-body"><!--?lit$640821808$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$640821808$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$640821808$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$640821808$-->Oct 03, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2402088?query=recirc_Semantic" target="_self">Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis</a></div><div class="mlt-article-authors"><!--?lit$640821808$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$640821808$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$640821808$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$640821808$-->May 12, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2115542?query=recirc_Semantic" target="_self">Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection</a></div><div class="mlt-article-authors"><!--?lit$640821808$-->S. Segal-Maurer and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$640821808$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$640821808$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$640821808$-->Dec 30, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2108793?query=recirc_Semantic" target="_self">Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children</a></div><div class="mlt-article-authors"><!--?lit$640821808$-->A. Turkova and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$640821808$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$640821808$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$640821808$-->Feb 15, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2312556?query=recirc_Semantic" target="_self">HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation</a></div><div class="mlt-article-authors"><!--?lit$640821808$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$640821808$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$640821808$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$640821808$-->May 12, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2204376?query=recirc_Semantic" target="_self">Lenacapavir for HIV-1 — Potential Promise of a Long-Acting Antiretroviral Drug</a></div><div class="mlt-article-authors"><!--?lit$640821808$-->J. Marrazzo</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1909512?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1909512" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1909512.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1909512"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1904398" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra1808012" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Hereditary Angioedema</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f1.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/ced5a908-c07e-46b8-bcef-ba4bab38c549/assets/images/large/nejmoa1909512_f1.jpg" height="3438" width="2217" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Trial Design, Screening, Randomization, and Treatment.</div><div class="notes"><div role="doc-footnote">Panel A shows the trial design scheme, which includes screening, induction, maintenance, and extension phases. During the screening phase, adults who met the inclusion criteria were enrolled in the trial; key exclusion criteria were previous use of antiretroviral therapy (ART), detection of hepatitis B virus (HBV) surface antigen, and the presence of nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance mutations other than the K103N mutation. During the induction phase, a single-tablet regimen of dolutegravir, abacavir, and lamivudine (DTG–ABC–3TC) was administered once daily for 20 weeks; those who had side effects in association with this therapy or were positive for HLA-B*5701 received dolutegravir plus two nucleoside reverse-transcriptase inhibitors other than abacavir. During randomization, participants were randomly assigned to continue the current oral therapy or switch to long-acting therapy during the maintenance phase. Participants in the long-acting–therapy group received oral lead-in therapy with cabotegravir (CAB) plus rilpivirine (RPV), followed by injections of long-acting formulations: initial loading injections of 600 mg of cabotegravir and 900 mg of rilpivirine were administered at week 4, and subsequent injections of 400 mg of cabotegravir and 600 mg of rilpivirine were administered every 4 weeks beginning at week 8. In this ongoing trial, participants who discontinue or complete long-acting therapy enter a 52-week long-term follow-up phase. Participants in the oral-therapy group who maintain viral suppression have the option to switch to long-acting therapy during the extension phase. Panel B shows participants who underwent screening, randomization, and treatment. Overall, 566 adults were randomly assigned to treatment; 180 adults who underwent screening were not assigned to treatment, primarily because they did not meet the eligibility requirements (149 participants). Of those 180 participants, 65 were excluded from the trial before randomization, primarily because they did not meet the viral suppression criterion while receiving oral induction therapy; 2 withdrew before receiving induction therapy. Treatment was initiated in 283 participants in each treatment group (intention-to-treat exposed population). The safety and intention-to-treat exposed populations were identical.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1909512_f2.jpg"><img src="/cms/10.1056/NEJMoa1909512/asset/cb3851ef-7b0a-49d8-866b-d4255b86e7b6/assets/images/large/nejmoa1909512_f2.jpg" height="3197" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Plasma Concentration–Time Profiles.</div><div class="notes"><div role="doc-footnote">Shown are the median plasma concentration–time profiles for cabotegravir (Panel A) and rilpivirine (Panel B) in 278 participants who received monthly injections of long-acting therapy. 𝙸 bars indicate the 5th and 95th percentiles. Dashed lines indicate the in vitro protein-adjusted 90% inhibitory concentration (PA-IC<sub>90</sub>). Predose plasma concentrations are shown.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline, Intention-to-Treat Exposed Population.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Outcomes at Week 48.</div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events during the Maintenance Phase.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/12" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 12</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 19, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1912658" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Surgery versus Conservative Care for Persistent Sciatica Lasting 4 to 12 Months</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.S. Bailey and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 19, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1906759" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H.T. Olsen and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/special-report" class="issue-item_type">Special Report</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 19, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMsr1912628" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Screening and Treatment Program to Eliminate Hepatitis C in Egypt</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">I. Waked and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1909512%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1909512&amp;pubId=41288603&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1909512%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1909512&amp;pubId=41288603&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06463300654450805" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d61dfeb446f1b7-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d61dfeb446f1b7-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d61dfeb446f1b7-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d61dfeb446f1b7-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d61dfeb446f1b7-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d61dfeb446f1b7-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d61dfeb446f1b7-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d61dfeb446f1b7-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d61dfeb446f1b7-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d61dfeb446f1b7-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d61dfeab9df1b7',t:'MTc0OTUyOTY1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d61dfeab9df1b7&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-transactionid="fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" id="captureIFrame_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" target="captureIFrame_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="capture_screen"><input id="capture_signIn_js_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="js_version"><input id="capture_signIn_transactionId_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" type="hidden" class="capture_transactionId_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="capture_transactionId"><input id="capture_signIn_form_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="form"><input id="capture_signIn_flow_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="flow"><input id="capture_signIn_client_id_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="client_id"><input id="capture_signIn_redirect_uri_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="redirect_uri"><input id="capture_signIn_response_type_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="response_type"><input id="capture_signIn_flow_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="flow_version"><input id="capture_signIn_settings_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="settings_version"><input id="capture_signIn_locale_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="locale"><input id="capture_signIn_recaptcha_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_fbvipj1vdpv5vmqyc2newf6xrsoblsyanstp7brg" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><ols-vojjrdclbnmp></ols-vojjrdclbnmp><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1909512?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script></body></html>